Remove 2023 Remove Medical Remove Safety
article thumbnail

U.S. FDA Approves Bimekizumab-bkzx (Bimzelx, UCB) for HS

The Dermatology Digest

Bimekizumab, an interleukin 17F (IL-17F) and IL-17A blocker, is now the third medication approved for HS, joining adalimumab (Humira, AbbVie) and its biosimilars and secukinumab (Cosentyx, Novartis). The safety profile of bimekizumab was consistent with safety data seen in previous trials across indications with no new safety signals.

Safety 78
article thumbnail

ASDSA Calls on States to Protect Patients from Counterfeit Neurotoxins

The Dermatology Digest

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Fenbendazole Joe Tippens Protocol: A Simple Step-by-Step Guide (2023)

Aesthetics Advisor

Disclaimer: We in no way endorse the Joe Tippens Cancer Protocol as a cure for cancer, and as always, you should consult your physician before starting any new medications or treatment plans. Click here to buy medical-grade CBD Oil >> (use code RETHN2 for a 20% discount!) What Is Fenbendazole?

Therapy 69
article thumbnail

Increasing Rate of Medical Mistakes and Misdiagnosis

Aesthetics Advisor

Medical errors remain a leading cause of death in the U.S., 2 Describing diagnostic errors as "the most under-resourced public health crisis we face," researchers with Johns Hopkins School of Medicine said the public is largely unaware of the full scope of medical misdiagnoses in the U.S. 6 For instance, only about 1.5%

Medical 36
article thumbnail

And Then There Were Six…FDA Green Lights Hugel’s Toxin for Glabellar Lines

The Dermatology Digest

Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the second half of 2024. Hugel resubmitted its application in October 2022 and was denied approval again in 2023. Now the toxin is approved in 63 countries, including the US, China, and Europe. and Europe.

article thumbnail

7 Best Mouthwashes for COVID-19 according to Evidence (2023)

Aesthetics Advisor

Mouthwash is part of the FLCCC I-PREVENT Protocol Best Mouthwashes for COVID-19 according to evidence for 2023 There are lots of great mouthwashes out there, and this list is by no means complete. The study is published in the Journal of Medical Microbiology (2022). The study is published in the Journal of Medical Microbiology (2022).

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. We will, for sure, have new medications for chronic urticaria.”